Evidence map›Paper›PMID 30650123›Full record

ArticlePloS one2019

Therapeutic Fc fusion protein misfolding: A three-phasic cultivation experimental design.

Atefeh Ghorbani Aghdam, Saeed Moradhaseli, Farnoush Jafari, Paria Motahari, Sepideh Samavat, Rasoul Mahboudi, Shayan Maleknia

Abstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Atefeh Ghorbani AghdamBiopharmaceutical Research Center, Aryogen Pharmed Inc., Alborz University of Medical Science, Karaj, Iran.
Saeed MoradhaseliBiopharmaceutical Research Center, Aryogen Pharmed Inc., Alborz University of Medical Science, Karaj, Iran.
Farnoush JafariBiopharmaceutical Research Center, Aryogen Pharmed Inc., Alborz University of Medical Science, Karaj, Iran.
Paria MotahariBiopharmaceutical Research Center, Aryogen Pharmed Inc., Alborz University of Medical Science, Karaj, Iran.
Sepideh SamavatBiopharmaceutical Research Center, Aryogen Pharmed Inc., Alborz University of Medical Science, Karaj, Iran.
Rasoul MahboudiBiopharmaceutical Research Center, Aryogen Pharmed Inc., Alborz University of Medical Science, Karaj, Iran.
Shayan MalekniaBiopharmaceutical Research Center, Aryogen Pharmed Inc., Alborz University of Medical Science, Karaj, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell culture process optimization is a critical solution to most of the challenges faced by the pharmaceutical manufacturing. One of the major problems encountered in large-scale production of therapeutic proteins is misfolded protein production. The accumulation of misfolded therapeutic proteins is an immunogenic signal and a risk factor for immunogenicity of the final product. The aim of this study was the statistical optimization of three-phasic temperature shift and timing for enhanced production of correctly folded Fc-fusion protein. The effect of culture temperatures were investigated using the biphasic culture system. Box-Behnken design was then used to compute temperature and time of shifting optimum. Response surface methodology revealed that maximum production with low level of misfolded protein was achieved at two-step temperature shift from 37°C to 30°C during the late logarithmic phase and 30°C to 28°C in the mid-stationary phase. The optimized condition gave the best results of 1860 mg L-1 protein titer with 24.5% misfolding level. The validation experiments were carried out under optimal conditions with three replicates and the protein misfolding level was decreased by two times while productivity increased by ~ 1.3-fold. Large-scale production in 250 L bioreactor under the optimum conditions was also verified the effectiveness and the accuracy of the model. The results showed that by utilizing two-step temperature shift, productivity and the quality of target protein have been improved simultaneously. This model could be successfully applied to other products.

Indexed as

AnimalsBioreactorsCHO CellsCricetulusImmunoglobulin Fc FragmentsModels, TheoreticalProtein FoldingRecombinant Fusion ProteinsTemperatureImmunoglobulin Fc FragmentsRecombinant Fusion Proteins

Identifiers

PMID30650123
PMCPMC6334962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.